Fawzy Amal, Gaafar Rabab, Kasem Fatma, Ali Shawkey S, Elshafei Mostafa, Eldeib Mahmoud
Clinical Pathology Department, NCI, Cairo University, Egypt.
J Egypt Natl Canc Inst. 2012 Mar;24(1):41-5. doi: 10.1016/j.jnci.2011.12.006. Epub 2012 Jan 17.
Angiogenesis is an essential process in cancer growth maintenance, and metastasis. Angiopoietin-2 promotes tumor angiogenesis by priming the vasculature and potentiating the effects of cytokines at the front of active neovascularization. Enhanced expression of angiopoietin-2 has been reported in lung cancer tissue. Survivin is one of the inhibitors of apoptosis protein that has been shown to play a key role in cancer progression, and in tumor angiogenesis. Also plays a key role in tumor cell resistance to anticancer agents and ionizing radiation.
To measure the serum levels of angiopoietin-2 and survivin as possible angiogenic factors in lung cancer patients with the assessment of their interrelationships and clinical significance.
Patients with lung cancer as NSCLC (n=70) and healthy volunteers (n=10) were enrolled. Serum angiopoietin-2 and survivin concentrations were measured using enzyme-linked immunosorbent assay (ELIZA).
Median serum angiopoietin-2 levels with lung cancer (2730pg/mL) ranged from 1171 to 6541pg/mL was higher than the median of the control group (1795pg/mL) ranged from 1076 to 2730/mL, p<0.001. Median serum survivin levels were also higher in patients with lung cancer (53.0pg/mL) ranged from 39.3 to 96.3pg/mL than the median of the control group (48.8pg/mL) ranged from 38.0 to 74.6pg/mL, but did not reach statistical significance p=0.206. In all patients with lung cancer, serum angiopoietin-2 was not significantly correlated with survivin (r=0.073, p=0.657). Neither serum angiopoietin-2 nor survivin showed significant relation with the serum angiopoietin-2 or survivin levels depending on the cell types, stage progression, and metastasis among the patients with NSCLC.
Our study suggests that serum angiopoietin-2 is a useful marker for the diagnosis of NSCLC by ELIZA technique.
血管生成是癌症生长维持及转移过程中的一个重要环节。血管生成素-2通过使血管系统致敏并增强细胞因子在活跃新生血管形成前沿的作用来促进肿瘤血管生成。据报道，血管生成素-2在肺癌组织中的表达增强。生存素是凋亡抑制蛋白之一，已被证明在癌症进展及肿瘤血管生成中起关键作用，在肿瘤细胞对抗癌药物及电离辐射的耐药性方面也起关键作用。
检测肺癌患者血清中血管生成素-2和生存素作为可能的血管生成因子的水平，并评估它们之间的相互关系及临床意义。
纳入非小细胞肺癌（NSCLC）患者70例及健康志愿者10例。采用酶联免疫吸附测定（ELISA）法检测血清血管生成素-2和生存素浓度。
肺癌患者血清血管生成素-2水平中位数为2730pg/mL（范围1171至6541pg/mL），高于对照组中位数1795pg/mL（范围1076至2730pg/mL），p<0.001。肺癌患者血清生存素水平中位数为53.0pg/mL（范围39.3至96.3pg/mL），高于对照组中位数48.8pg/mL（范围38.0至74.6pg/mL），但差异无统计学意义，p=0.206。在所有肺癌患者中，血清血管生成素-2与生存素无显著相关性（r=0.073，p=0.657）。在NSCLC患者中，血清血管生成素-2和生存素与血清血管生成素-2或生存素水平均未显示出与细胞类型、分期进展及转移的显著关系。
我们的研究表明，通过ELISA技术检测血清血管生成素-2是诊断NSCLC的一个有用标志物。
